Mereo BioPharma Group plc (MAH0.SG)

3,1500 +0,0100 (+0,32%) Börsenschluss: 03:31PM CEST

Mereo BioPharma Group plc

One Cavendish Place
4th Floor
London W1G 0QF
United Kingdom
44 33 3023 7300
https://www.mereobiopharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 33

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Denise Vera Scots-Knight Ph.D.	Co-Founder, CEO & Executive Director	831,67k	N/A	1959
Mr. Charles Edward Sermon	Co-Founder, General Counsel, Business Development & Company Secretary	584,4k	N/A	1969
Ms. Christine Fox CPA	Chief Financial Officer	532,09k	N/A	1981
Dr. John P. Richard M.B.A.	Co-Founder & Chief Business Officer	N/A	N/A	1957
Dr. John A. Lewicki Ph.D.	Chief Scientific Officer	N/A	N/A	1952
Dr. Jackie Parkin	Senior VP & Therapeutic Head	N/A	N/A	1958
Ms. Alexandra Hughes-Wilson	Chief of Patient Access & Commercial Planning	N/A	N/A	1971
Dr. Suba Krishnan	Senior Vice President of Clinical Development	N/A	N/A	1965
Mr. Bo Kara	Senior VP and Head of Pharmaceutical Development & CMC	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Corporate Governance

Mereo BioPharma Group plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.